Orthostatic hypotension

Aug 26, 2019

The global orthostatic hypotension drugs market at a CAGR of almost 8% during the forecast period

Jul 22, 2019

Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress

Jun 18, 2019

Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress

Mar 25, 2019

Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress

Jan 28, 2019

Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

Aug 23, 2018

How Low is Too Low? Study Highlights Serious Risks for Intensive Blood Pressure Control

Aug 01, 2018

Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

May 17, 2018

Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension

Mar 28, 2018

An Increase in Heart Rate as Blood Pressure Falls Could Be Early Sign of Neurological Disease